company background image
ULTI logo

Ultimovacs OB:ULTI Stock Report

Last Price

kr7.97

Market Cap

kr274.2m

7D

25.9%

1Y

-93.0%

Updated

28 Mar, 2024

Data

Company Financials +

Ultimovacs ASA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ultimovacs
Historical stock prices
Current Share Pricekr7.97
52 Week Highkr178.60
52 Week Lowkr6.07
Beta1.16
1 Month Change-94.09%
3 Month Change-93.51%
1 Year Change-93.01%
3 Year Change-87.47%
5 Year Changen/a
Change since IPO-74.29%

Recent News & Updates

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Feb 21
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Recent updates

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Feb 21
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Oct 26
Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Oct 05
Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

May 19
Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27
Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23
We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13
Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Insider Buying: The Ultimovacs ASA (OB:ULTI) Chief Executive Officer Just Bought 12% More Shares

Jan 14
Insider Buying: The Ultimovacs ASA (OB:ULTI) Chief Executive Officer Just Bought 12% More Shares

Shareholder Returns

ULTINO BiotechsNO Market
7D25.9%2.6%1.2%
1Y-93.0%-68.7%4.1%

Return vs Industry: ULTI underperformed the Norwegian Biotechs industry which returned -68.7% over the past year.

Return vs Market: ULTI underperformed the Norwegian Market which returned 5.4% over the past year.

Price Volatility

Is ULTI's price volatile compared to industry and market?
ULTI volatility
ULTI Average Weekly Movement28.3%
Biotechs Industry Average Movement9.3%
Market Average Movement5.3%
10% most volatile stocks in NO Market10.3%
10% least volatile stocks in NO Market2.8%

Stable Share Price: ULTI's share price has been volatile over the past 3 months.

Volatility Over Time: ULTI's weekly volatility has increased from 17% to 28% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201124Carlos de Sousahttps://ultimovacs.com

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Ultimovacs ASA Fundamentals Summary

How do Ultimovacs's earnings and revenue compare to its market cap?
ULTI fundamental statistics
Market capkr274.22m
Earnings (TTM)-kr189.24m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ULTI income statement (TTM)
Revenuekr0
Cost of Revenuekr0
Gross Profitkr0
Other Expenseskr189.24m
Earnings-kr189.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 07, 2024

Earnings per share (EPS)-5.50
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ULTI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.